PROF Archives - Page 6 of 7

Developments Markets

Mayo Clinic listed on TULSA center locator page, indicating Profound Medical’s first sale to a teaching hospital

The Mayo Clinic has just been listed as a new TULSA-PRO site, representing the first sale of the system to a teaching hospital by the technology’s developer, Profound Medical Profound Medical (TSX:PRN; NASDAQ:PROF)...

July 9, 2020

Markets

Raymond James adds Profound Medical to “analyst current favorite”

Raymond James added Profound Medical (TSX:PRN; NASDAQ:PROF) as an “analyst current favorite,” maintaining a “strong buy” recommendation, after AstraZeneca and Merck received FDA approval for their PARP inhibitor drug...

May 22, 2020

Developments

Nominees announced for 2020 Bloom Burton award

Arun Menawat, CEO of Profound Medical (NASDAQ:PROF; TSX:PRN), was one of three nominees for the 2020 Bloom Burton award, which honors an individual who has made the most significant contribution to Canada’s innovative...

April 30, 2020

Developments

Profound Medical launches TULSA patient website in U.S.

Profound Medical (NASDAQ:PROF; TSX:PRN) launched a newly designed TULSA Procedure website, for residents of the U.S. suffering from a prostate condition. “This new site aims to be credible and focused on providing clear...

April 3, 2020

Markets

Cowen starts Profound Medical at OP; PT $15 (U.S.)

Cowen launched coverage of Profound Medical (NASDAQ:PROF; TSX:PRN) with an “outperform” rating and $15 (U.S.) price target. The stock closed at $9.74 on March 31. “[Profound’s] TULSA-PRO is a proprietary platform that...

April 1, 2020

Developments

Kasraeian Urology treats first Jacksonville patient with Profound’s TULSA-PRO

Dr. Ali Kasraeian of the renowned Kasraeian Urology in Jacksonville, FL, in partnership with Vituro Health, treated their first patient with Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO medical device for...

March 27, 2020

Developments

Profound Medical’s TULSA-PRO now available at Georgia’s renowned Busch Center

Georgia’s renowned Busch Center is now offering Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO procedure to treat unhealthy prostate tissue. The technology, which was cleared by the FDA in August 2019, provides...

March 26, 2020

Markets

Mackie Research ups Profound Medical to speculative buy

Mackie Research upgraded Profound Medical (TSX:PRN; NASDAQ:PROF) to “speculative buy” from “hold,” but reduced its price target to $16.20 from $26.10 due to the anticipated impact of the coronavirus. The stock closed at...

March 24, 2020

Markets

Raymond James sees Profound Medical insulated from COVID-19 fallout

Raymond James reiterated that Profound Medical (TSX:PRN; NASDAQ:PROF) remains its “analyst current favorite” and “2020 Best Pick,” saying Profound is “particularly insulated from the current economic fallout of COVID-19...

March 12, 2020

Developments

Profound Medical retires bank debt ahead of schedule

Profound Medical (TSX:PRN; NASDAQ:PROF) retired its $12.5-million in principal amount loan with Canadian Imperial Bank of Commerce, maturing July 29, 2022. “We are pleased to have repaid the CIBC loan almost 30 months...

February 5, 2020

Tag - PROF

Mayo Clinic listed on TULSA center locator page, indicating Profound Medical’s first sale to a teaching hospital

Raymond James adds Profound Medical to “analyst current favorite”

Nominees announced for 2020 Bloom Burton award

Profound Medical launches TULSA patient website in U.S.

Cowen starts Profound Medical at OP; PT $15 (U.S.)

Kasraeian Urology treats first Jacksonville patient with Profound’s TULSA-PRO

Profound Medical’s TULSA-PRO now available at Georgia’s renowned Busch Center

Mackie Research ups Profound Medical to speculative buy

Raymond James sees Profound Medical insulated from COVID-19 fallout

Profound Medical retires bank debt ahead of schedule

General

More